Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05742711
Other study ID # CS015
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 16, 2023
Est. completion date November 2024

Study information

Verified date June 2023
Source DyAnsys, Inc.
Contact Dr. Sahithya Sriman
Phone +91-9840226923
Email sahithyaadhithyan@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pain relief following laparotomy surgery requires a variety of techniques including invasive ones like epidural or nerve blocks along with different classes of drugs, out of which opioids are most predominant. Each of these drugs have with their own set of advantages and also side effects. An ideal common system of analgesia is not possible due to patient variability. And no drug is devoid of side effects. Hence the aim is to ensure effective analgesia using drugs or techniques which are minimally invasive with negligible side effects.


Description:

Efficient post operative pain relief is an essential part of comprehensive recovery of patients. Conventional method of pain management of laparotomy surgeries in CA endometrium and cervix patients involves invasive techniques like epidural or selective nerve block coupled with a varied choice of analgesics like opioids, NSAID or acetaminophen, wherein each drug is associated with its own set of contraindications and side effects. Despite advances in analgesic regimen including multimodal analgesic regimen, opioids have been observed to remain the mainstay postoperative analgesia in cancer patients despite its well-established side effects. This double-blinded prospective interventional study is conducted to explore the alternative of percutaneous electrical nerve stimulation (PENS) devices for effective pain relief with minimal to no side-effects. The device will have tiny needles and a battery system that will be placed on and behind the patient's ear when they are under anesthesia. It acts by stimulating nerves around ear region by series of pain free impulse generation leading to centrally (brain) mediated response by altering certain chemical substances responsible for causing pain thereby providing relief for the patient.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date November 2024
Est. primary completion date November 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >18 yrs - Diagnosed with CA-endometrium OR CA -cervix of stage I/II and post RT CA cervix patients coming for hysterectomy - Elective surgery - Informed consent obtained - ASA (American Society of Anaesthesiology) physical status 1-3 Exclusion Criteria: - Patient refusal - Cancer cervix other than the stages mentioned in inclusion criteria ASA PS >3 - Emergency surgery, Laparoscopic and robotic procedures - Unplanned postoperative ventilation - Allergy/sensitivity to adhesive - Active skin infection/lesion in the ear region - H/O of seizure or cerebral disease - H/O chronic pain and prolonged analgesic usage - H/O opioid dependence - H/O anxiety or psychiatric illness requiring treatment - Pre-existing implantable/ electronic on demand device - Patients who might require MRI in the study period - Patients with transmissible diseases - Patients with coagulopathies - Absolute or relative contraindication to drugs used in the study

Study Design


Intervention

Device:
Primary Relief
Continuous neurostimulation with a set of pre-assigned stimulation parameters.
Primary Relief - Sham Device
Standard treatment with the application of sham device shall be followed with additional analgesics available if necessary.

Locations

Country Name City State
India Cancer Institute,(Wia) Chennai Tamil Nadu

Sponsors (1)

Lead Sponsor Collaborator
DyAnsys, Inc.

Country where clinical trial is conducted

India, 

References & Publications (2)

Arponrat P, Pongrojpaw D, Tanprasertkul C, Suwannarurk K, Bhamarapravatana K. Postoperative Pain Relief in Major Gynaecological Surgery by Perioperative Parecoxib Administration: Thammasat University Hospital Study. J Med Assoc Thai. 2015 Jul;98(7):636-42 — View Citation

Pogatzki-Zahn E, Kutschar P, Nestler N, Osterbrink J. A Prospective Multicentre Study to Improve Postoperative Pain: Identification of Potentialities and Problems. PLoS One. 2015 Nov 24;10(11):e0143508. doi: 10.1371/journal.pone.0143508. eCollection 2015. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Rating Scale (NRS) The primary goal is to evaluate the efficacy of PENS treatment in the change in postoperative pain after cancer surgery compared to the control group. The pain is measured using the numerical rating scale (NRS). Pain Score will be measured on a scale (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome) 0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours. Outcomes will be reported as an average over each individual postoperative day and as an average over 5 days independently for rest.
Secondary Overall Postoperative analgesia and opioid requirement To evaluate the effect of treatment in reducing the overall postoperative analgesia and opioid requirement. We will record the total dose and duration of additional analgesics required from the immediate postoperative period till pod 4 in iv morphine equivalents. 0 - 4 days, duration and dose of all prescriptions are recorded.
Secondary Patient Ambulation Evaluate the ease of patient ambulation by assessing associated Numeric Rating Scale (NRS) score (0 = no pain;10 = worst imaginable pain; lower scores indicate better outcome) 1 - 4 days; 24 hours, 36 hours, 48 hours, 72 hours, 96 hours.
Secondary Record of Participant Bowel Movement Patterns Onset of Bowel Movements - POD 1/POD 2/ POD 3/ > POD3 0 - 4 days; Whenever the patient experiences the bowel movement.
Secondary Richmond Agitation Sedation Scale (RASS) Compare Richmond Agitation Sedation Scale (RASS) score at a different time point during the follow-up time. RASS score will be measured on a scale (from -5 = Unarousable to +4 = Combative where 0 = Alert and calm) 0 - 4 days; 0 hours, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours.
Secondary Patient Discomfort Patient Discomfort due to device (Yes / no) Time Frame: 0 - 4 days; Whenever the patient experiences the discomfort.
Secondary Bleeding Bleeding at the site of device placement (Yes / No) Time Frame: 0 - 4 days; Whenever the patient experiences bleeding.
Secondary Interference with Daily Activities Interference with activities of daily living due to the device (Yes/No) Time Frame: 0 - 4 days; Whenever the patient experiences disruption in daily activities.
See also
  Status Clinical Trial Phase
Completed NCT03653819 - High Intensity Interval Training (HIIT) for Patients With Cancer-related Lymphedema in the Lower Limbs N/A
Active, not recruiting NCT00193739 - Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix Phase 3
Not yet recruiting NCT04999696 - Minimally Invasive Therapy Versus Open Radical Hysterectomy for Management of Early Stage Cervical Cancer N/A
Completed NCT02309658 - Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Phase 2
Completed NCT00193752 - Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix N/A
Recruiting NCT00154479 - The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus N/A
Recruiting NCT05179824 - Tempus Priority Study: A Pan-tumor Observational Study
Not yet recruiting NCT06147960 - Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer
Completed NCT05149248 - Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study Phase 2/Phase 3
Completed NCT00191100 - Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Phase 3
Completed NCT00193830 - High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix Phase 3
Completed NCT02865135 - Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer Phase 1/Phase 2
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Not yet recruiting NCT05824494 - Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors Phase 2
Active, not recruiting NCT05709730 - Follow-up of Cell Changes in the Cervix
Completed NCT00193791 - Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix N/A
Withdrawn NCT02312804 - Ph Ib/BGJ398/Cervix and Other Solid Tumors Phase 1
Recruiting NCT03452774 - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Completed NCT00193804 - A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix
Completed NCT04809727 - Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy N/A